Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68
- PMID: 7513255
Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68
Abstract
Cytotoxic T-lymphocytes (CTLs) specific for autologous human squamous cell cancer of the lung were generated by stimulation of peripheral blood lymphocytes with autologous tumor cells in vitro. The CTL line was >97% CD3+, CD8+, CD16- and produced tumor necrosis factor-alpha, gamma-interferon, and granulocyte-macrophage colony-stimulating factor after stimulation with autologous tumor. The CTLs lysed autologous tumor but failed to recognize autologous or histocompatibility leukocyte antigen-matched lymphoid cells, K562, or allogeneic tumor cells of several histological types. Antibody-blocking studies suggested that the CTLs recognized one or more antigens presented by the class I major histocompatibility complex molecule Aw68. To characterize these antigens further, histocompatibility leukocyte antigen Aw68 molecules were extracted from the squamous cell cancer of the lung tumor line by immunoaffinity chromatography, and the associated peptides were eluted in acid and separated by reversed-phase high-performance liquid chromatography. Reconstitution of the CTL epitope was evaluated by adding these peptides to autologous Epstein-Barr virus-transformed B-cells. Two peaks of reconstituting activity were observed, suggesting that these CTLs recognize at least two Aw68-associated peptides. This study confirms the existence of a CTL response against autologous human squamous cell cancer of the lung and suggests that this CTL response is directed against peptide epitopes presented by the class I major histocompatibility complex molecules. It is anticipated that this approach will permit identification of peptide epitopes for lung cancer-specific CTLs.
Similar articles
-
The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene.Cancer Res. 1998 Nov 15;58(22):5144-50. Cancer Res. 1998. PMID: 9823325
-
Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner.Int J Oncol. 2004 Dec;25(6):1537-42. Int J Oncol. 2004. PMID: 15547688
-
A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.Clin Cancer Res. 2000 Mar;6(3):979-86. Clin Cancer Res. 2000. PMID: 10741724
-
[Tumor-rejection antigens expressed on human squamous cell carcinoma].Hum Cell. 1995 Dec;8(4):149-54. Hum Cell. 1995. PMID: 8721083 Review. Japanese.
-
Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer.Cancer Res. 2013 Apr 15;73(8):2381-8. doi: 10.1158/0008-5472.CAN-12-3932. Epub 2013 Apr 11. Cancer Res. 2013. PMID: 23580578 Review.
Cited by
-
Activation by interferon-gamma of expression of ICAM-1 and MHC class II antigens in tumour cells from colorectal carcinomas.Clin Mol Pathol. 1995 Feb;48(1):M40-5. doi: 10.1136/mp.48.1.m40. Clin Mol Pathol. 1995. PMID: 16695974 Free PMC article.
-
Induction of auto-logous human cytotoxic T lymphocytes (CTL) from peripheral blood against tumor cells.Cytotechnology. 1997 Jan;23(1-3):197-203. doi: 10.1023/A:1007995013870. Cytotechnology. 1997. PMID: 22358536 Free PMC article. No abstract available.
-
Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies.Hum Vaccin Immunother. 2024 Dec 31;20(1):2303799. doi: 10.1080/21645515.2024.2303799. Epub 2024 Feb 12. Hum Vaccin Immunother. 2024. PMID: 38346926 Free PMC article. Review.
-
Targeted tumor cell death induced by autologous tumor-specific T lymphocyte recognition of wild-type p53-derived peptides.J Neurooncol. 2006 Jan;76(2):99-104. doi: 10.1007/s11060-005-4172-6. J Neurooncol. 2006. PMID: 16132498
-
Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo.J Exp Med. 2000 Dec 18;192(12):1755-62. doi: 10.1084/jem.192.12.1755. J Exp Med. 2000. PMID: 11120772 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Research Materials